• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Novexel

edit

Novexel SA, a pharmaceutical company, engages in the discovery and development of antibacterial and antifungal agents to treat bacterial and fungal infections. The company focuses on biology, medicinal chemistry, pharmacology, microbiology, and clinical development. It provides NXL201, an aminocandin anti-fungal agent; NXL104, an injectable beta-lactamase inhibitor to treat hospital infections that are caused by gram negative bacteria; NXL103, an oral streptogramin antibiotic to treat gram positive infections in the hospital setting and intravenous to oral switch; and NXL105, an anti-pseudomonal antibiotic. The company was founded in 2004 and is headquartered in Romainville, France.

Recent Milestones

edit

• 
  Novexel was acquired by AstraZeneca for $505M. (12/23/09)
  Posted 12/27/09 at 9:06pm via fiercebiotech.com
• 
  Novexel added Iain Buchanan as CEO.
  Posted 12/27/09 at 9:05pm
• 
  Novexel added Gordon Waldron as CFO.
  Posted 12/27/09 at 9:05pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/28/09

Sources

1. Novexel to be Acquired by AstraZeneca (fiercebiotech.com) [edit]